Print this Page

Ground View

To determine the issues of most concern to the California life sciences company CEOs, the 2013 survey sought their thoughts on a number of threats to the industry’ growth. Respondents were asked to rank a number of impactful issues that are implemented within the federal and state government. Much depends on the life sciences industry’s ability to access capital and preserve that capital with essential tax incentives and a clear regulatory path. The following snapshots with Aragon, Regulus, and Veracyte delve into how companies continue to innovate in difficult and uncertain environments.

CEO Survey: Rate each of these potential threats on a scale of 1-5, with 1 being least threatening and 5 being the most threatening.

Greatest Threats

This year’s respondents indicate the top three issues affecting the biomedical industry in California were limited or lack of access to capital, the FDA regulatory environment and government pricing.

CEO Survey: Rate the influence each of the STATE environmental regulations has on the industry’s ability to keep biomedical research, innovation and investment in California.

14a. Rate the influence each of the state environmental regulations has on the industry’s ability to keep biomedical research

In regard to environmental regulations, manufacturing restrictions were again deemed most important to respondents. Chemical bans and product stewardship were important to more than half of respondents.

CEO Survey: Rate the influence of each of the STATE tax incentives has for innovation on the industry’s ability to keep biomedical research, innovation and investment in California.

14b. Rate the influence of each of the state tax incentives has for innovation of the industry’s ability

When asked about tax incentives, the R&D tax credit was important to more than 98 percent of respondents. The treatment of net operating losses was also of major importance to more than 80 percent of respondents.

CEO Survey: Rate the influence each of these FEDERAL tax and finance issues has on the industry’s ability to advance biomedical research, innovation and investment in California.

15a. Rate the influence each of these federal tax and finance issues has on the industry’s ability to advance biomedical research

Federal tax and finance issues can have a great impact on the advancement of the biomedical industry. This year’s respondents felt strong support for R&D tax credits of the choices given. The majority of respondents felt that the therapeutic discovery project credit, SDBIR government funding, medical device manufacturer excise tax, corporate tax reform and innovation/patent box were all likely to affect the progress of the industry.

CEO Survey: How do each of these FEDERAL policy issues compare to last year?

How do each of these federal policy issues compare to last year?

When respondents were asked to compare to 2011, they indicated that FDA regulation had gotten slightly better whereas coverage and reimbursement policy as well as tax and finance incentives and science funding was worse than last year.

SNAPSHOT:
NEW CANCER TREATMENTS
Aragon Pharmaceuticals

Aragon Pharmaceuticals, Inc.
Aragon Pharmaceuticals, Inc.
“The ultimate goal is that cancer patients will receive more personalized and efficacious cancer treatment with lower toxicity and better quality of life.”

Richard Heyman, Ph.D., president and CEO, Aragon Pharmaceuticals

Read more…

SNAPSHOT:
NEW
DIAGNOSTICS
Veracyte

Veracyte
Veracyte
“We believe that diagnostics will play an ever-increasing role in helping physicians personalize care. The ability to utilize sophisticated technology to unlock molecular information allows physicians to provide patients with personalized treatment options in a way that was unthinkable a generation ago.”

Bonnie Anderson, Co-Founder and CEO, Veracyte

Read more…

SNAPSHOT:
IPOS
Regulus Therapeutics
(NASDAQ: RGLS)

Regulus Therapeutics
Regulus Therapeutics
“Our industry needs to focus considerable scientific and financial resources to uncover innovative, new biology that can be used to treat diseases with high unmet medical need or treat diseases with new, more patient-friendly regimens to improve cure rates.”

Kleanthis Xanthopoulos, Ph.D., President and CEO, Regulus Therapeutics

Read more…

Permanent link to this article: http://www.californiabiomedreport.com/developing-new-products-ground-view/